Nuvation Bio (NYSE:NUVB) Director Robert Mashal Acquires 25,000 Shares

Posted by Francis Steltz on Jun 11th, 2026

Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) Director Robert Mashal acquired 25,000 shares of the stock in a transaction on Tuesday, June 9th. The shares were acquired at an average price of $4.73 per share, with a total value of $118,250.00. Following the transaction, the director directly owned 225,000 shares of the company’s stock, valued at $1,064,250. The trade was a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Nuvation Bio Price Performance

NUVB stock traded up $0.20 during trading on Thursday, hitting $4.78. 3,456,693 shares of the company’s stock traded hands, compared to its average volume of 4,387,448. Nuvation Bio Inc. has a 52 week low of $1.57 and a 52 week high of $9.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.24 and a current ratio of 7.44. The business has a fifty day simple moving average of $4.72 and a 200 day simple moving average of $5.89. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -11.10 and a beta of 1.52.

Nuvation Bio (NYSE:NUVB – Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.04. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. The business had revenue of $83.23 million during the quarter, compared to analyst estimates of $66.22 million. As a group, research analysts expect that Nuvation Bio Inc. will post -0.39 EPS for the current fiscal year.

Institutional Trading of Nuvation Bio

Several institutional investors and hedge funds have recently modified their holdings of NUVB. Price T Rowe Associates Inc. MD raised its stake in shares of Nuvation Bio by 852.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company’s stock valued at $24,270,000 after acquiring an additional 2,424,109 shares in the last quarter. Armistice Capital LLC raised its stake in shares of Nuvation Bio by 359.2% during the third quarter. Armistice Capital LLC now owns 2,296,000 shares of the company’s stock valued at $8,495,000 after acquiring an additional 1,796,000 shares in the last quarter. Capricorn Fund Managers Ltd bought a new stake in shares of Nuvation Bio during the fourth quarter valued at approximately $14,236,000. Millennium Management LLC raised its stake in shares of Nuvation Bio by 52.4% during the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock valued at $6,642,000 after acquiring an additional 1,298,131 shares in the last quarter. Finally, SymBiosis Capital Partners LLC bought a new stake in shares of Nuvation Bio in the 4th quarter valued at about $11,200,000. Institutional investors own 61.67% of the company’s stock.

Analyst Ratings Changes

NUVB has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Nuvation Bio in a research report on Tuesday, May 5th. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Nuvation Bio in a research report on Tuesday, May 5th. UBS Group lowered their price target on Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, March 3rd. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $20.00 price target on shares of Nuvation Bio in a research report on Tuesday, May 5th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

Read Our Latest Report on NUVB

Nuvation Bio Company Profile

(Get Free Report)

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.